Response to Comments: Voretigene Neparvovec-rzyl (Luxturna™)

Policy A56401 is a response-to-comments notice for Voretigene Neparvovec-rzyl (Luxturna) referencing LCD L37863 and L37873 and lists administrative comment and notice periods; it does not contain clinical coverage criteria. For specific indications, limitations, documentation requirements, and frequency limits, refer to the full LCDs L37863 and L37873 (effective May 6, 2019).

"This document is a response-to-comments notice for Voretigene Neparvovec-rzyl (Luxturna) and contains administrative comment-period dates only; it does not state clinical coverage criteria."

Sign up to see full coverage criteria, indications, and limitations.